| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $224.5M | +64.8% |
| Cost of Revenue | $87.4M | +34.2% |
| Gross Profit | $137.1M | +93.0% |
| R&D Expense | $62.3M | +28.6% |
| SG&A Expense | $171.4M | +30.1% |
| Operating Income | -$96.6M | +11.5% |
| Income Tax | $0 | — |
| Net Income | -$91.4M | +13.7% |
| EPS (Basic) | -$1.75 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $333.7M | +29.7% |
| Accounts Receivable | $83.5M | +72.6% |
| Inventory | $56.2M | +41.3% |
| Current Assets | $481.8M | +37.4% |
| Total Assets | $534.0M | +31.9% |
| Current Liabilities | $53.1M | +15.7% |
| Long-term Debt | $51.5M | +0.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$99.2M | +8.1% |
| Capital Expenditures | $4.4M | -82.5% |
| Investing Cash Flow | -$4.4M | +82.5% |
| Financing Cash Flow | $180.1M | +7.3% |
| Free Cash Flow | -$103.6M | +22.2% |
| +21.9% |
| EPS (Diluted) | -$1.75 | +21.9% |
| Total Liabilities |
| $131.8M |
| +6.3% |
| Stockholders' Equity | $402.2M | +43.3% |